Analysed ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) News Sources
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial
31-03-2026
marketbeat.com
Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened
01-04-2026
yahoo.com
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
02-04-2026
yahoo.com
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
02-04-2026
biopharmadive.com
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
06-04-2026
yahoo.com
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
17-04-2026
yahoo.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01-05-2026
yahoo.com
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
04-05-2026
yahoo.com
What is the current price of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)?
The current price of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) is $8.54.
ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) absolute price change since previous trading day?
The absolute price change of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) since the previous trading day is $0.22.
ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) percentage price change since previous trading day?
The percentage price change of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) since the previous trading day is 2.6442%.
What is the most recent average sentiment score for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)?
The most recent average sentiment score for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)?
The most recent sentiment for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) is .
SEC-8K** Filing Available For ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.